ABBV241220P270000
- 0.00
- 0.000.00%
AbbVie Newsroom
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $220
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Alcon (ALC) and Humana (HUM)
Express News | Abbvie : Piper Sandler Raises Target Price to $220 From $212
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
AbbVie (ABBV.US) has reached an acquisition agreement to expand its presence in the field of autoimmune diseases.
AbbVie (ABBV.US) announced that it has reached a final agreement with Nimble Therapeutics.
EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease
AbbVie Announces Leadership Change With New Appointment
AbbVie: David R. Purdue Will Be Senior Vice President, Controller
AbbVie: Kevin K. Buckbee, Senior Vice President, Controller, Plans to Retire From Controller Role Effective March 1
This Drugmaker's (ABBV) Parkinson's Medication Just Cleared A Key Hurdle – Is It Primed For A Monster Year In 2025?
AbbVie to Buy Nimble Therapeutics
AbbVie: Nimble Shareholders Eligible for Potential Development Milestone Payment >ABBV
Express News | Abbvie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
Unlearn's 2024 Achievements Drive Innovation in AI for Clinical Development
Express News | Hungary's Richter CEO Says Previous Pace of Growth in Dividend Payouts Cannot Be Maintained
Express News | Hungary's Richter CEO Says Company Eyeing Acquisition Targets for Next Year